Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Evotec SENASDAQ: EVO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -€19.3M, compared with €35.43M a year earlier. Trailing-twelve-month financing cash flow was -€89.88M. Over 3 fiscal years it compounded at -19.0% a year.

Context

  • Financing cash flow amounted to 4.1% of revenue in FY2025, down 16.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near -€19.3M or moves back toward the trailing-twelve-month quarterly average of -€22.47M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€19.3M-55.9% QoQ
Last fiscal yearDec 2025
-€30.93M-80.8% YoY
LTMMar 2026
-€89.88M-28.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-154.5%——
1 year-80.8%——
3-year CAGR-19.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

EUR · from the cash flow

Latest · FY2025
(30.93M) EUR
Year-over-year change
+80.8%

Financing Cash Flow vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.4% is the 6th highest of 11, against a peer median of -3.5%.
  • Financing cash flow amounts to 12.1% of revenue for EVO, versus a peer median of 22.1%.
EVO Competitors
Financing Cash Flow for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$759.69M USD+242.5%+93.5%839.5%
TDOCTeladoc Health, Inc.LTM Mar 2026$554.87M USD-7669.8%—22.1%
NVCRNovoCure LimitedLTM Mar 2026$456.76M USD-579.0%—67.7%
PCRXPacira BioSciences, Inc.LTM Mar 2026$426.03M USD-2578.9%-2.7%58.0%
ALVOAlvotechLTM Mar 2026$275.7M USD+74.2%-13.9%49.3%
AZTAAzenta, Inc.LTM Sep 2026$119.5M USD+1145.9%-47.8%19.2%
TLRYTilray Brands, Inc.LTM Feb 2026$116.27M USD-30.4%+4.3%9.8%
PHVSPharvaris N.V.LTM Sep 2026€112.22M EUR-30.3%+164.8%—
EVOEvotec SELTM Mar 2026€89.88M EUR-28.4%-19.0%12.1%
HROWHarrow Health, Inc.LTM Mar 2026$36.17M USD+23.2%—13.5%
SDGRSchrödinger, Inc.LTM Sep 2026$4.14M USD+45.0%+11.6%1.5%
Peer median (excluding EVO) —-3.5%+4.3%22.1%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.